KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance MAHWAH, NJ – August 5, 2026 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development,
How this was made
The 30-second read
Why it matters
Traders can update valuation and positioning based on the narrowed revenue and gross margin targets, improved gross margin and net income, and management’s stated strategic shift in U.S. oncology regulatory approach.
Market read
The filing provides fresh, quantitative guidance and profitability updates that can drive near-term repricing and trading decisions.
What to watch
Pharma services and clinical trials revenue fell 35% YoY, and international growth is expected to moderate due to European launch conversion timing, which could cap upside if execution slips.
Background
This is an SEC 8-K with the company’s Q2 2026 financial results and an updated full-year 2026 guidance range.
Ticker impact
KORU Medical reported Q2 2026 results and narrowed FY 2026 guidance, including revenue $47.5-$48.5M and gross margin 62%-64%.
Moderate positive bias for the next few sessions as traders price in the updated FY revenue and margin outlook.
The filing is a primary-source earnings and guidance update with specific quantitative targets and profitability improvements, which typically drives immediate repricing for small/mid-cap biotech/medtech names.
Market effects
Signals demand strength in subcutaneous infusion and SCIg-related volumes, potentially supportive for peers focused on large-volume subcutaneous delivery.
International core revenue growth (up 59.1% YoY) highlights Europe conversion dynamics as a key driver.
Limited broader macro relevance; primarily company-specific medtech execution and regulatory strategy (510(k) withdrawal).
Counterpoint
Withdrawing the U.S. 510(k) for FreedomEDGE with Phesgo could be viewed as a near-term setback to U.S. oncology growth plans despite the shift to alternative higher-volume molecules.
Key entities
- companyKORU Medical Systems, Inc.
NASDAQ-listed medical technology company reporting Q2 2026 results and updating FY 2026 guidance.
- productFreedomEDGE
U.S. oncology device referenced in the company’s decision to withdraw a 510(k) application.
- productPhesgo
Referenced in the withdrawn 510(k) application tied to FreedomEDGE.